| Patient | Vincent van Gogh |
|---|---|
| Date of birth | 1990-03-30 |
| Identifiers | MRN HR-NI010-SYN; SSN (made up) 000-10-3198 |
| Document date | 2026-04-20 |
| Author | Elise Verhoeven, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review with the 12-week metabolic check. [S]
Mr. van Gogh returns three months after his first visit, fifteen weeks after aripiprazole was started in hospital, fasting for his blood tests. He has had no voices, suspiciousness, or confusion since the six-week visit. He takes aripiprazole 10 mg and naltrexone every morning. He sleeps about seven hours and goes to bed by midnight; he noticed once that after a late night of work he felt a rush of ideas the next day, and he went to bed early as his plan says. He paints most days, outdoors now that spring has come, and has sold two paintings. He drinks one glass of wine with dinner on most days and none on two days a week. His appetite is a little greater than before. His mood is steady; he has not had thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Psychotic symptoms | None since the six-week visit |
| Early warning signs | One day of racing ideas after a late night; managed with sleep |
| Sleep | About seven hours at regular times |
| Alcohol | One glass of wine with dinner on most days; two alcohol-free days a week |
| Mood | Steady; PHQ-9 6; item 9 scored 0 |
| Weight | Appetite slightly greater; weight up 1.7 kg since intake |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite a little greater; weight up 1.7 kg |
| Endocrine | Negative | No thirst or frequent urination |
| Neurological | Negative | No restlessness, stiffness, tremor, or seizures |
| Psychiatric | Negative | No voices or suspiciousness; mood steady; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) | One tablet by mouth once daily | Oral route | 2026-01-05 to 2026-02-02 | completed | S |
| Aripiprazole 15 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 to 2026-02-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet by mouth daily | Oral route | 2026-01-05 to 2026-07-20 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-16 | active | S |
| Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisia | One tablet by mouth twice daily | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 170 | cm | S |
| 2026-04-20 | Body weight | 65.7 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 74 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Fasting glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-20 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-20 | Cholesterol [Mass/volume] in Serum or Plasma | 191 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-04-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 50 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-20 | Triglyceride [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 10-40 U/L | Normal | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-56 U/L | Normal | S |
| 2026-04-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 8-61 U/L | Normal | S |
| 2026-04-20 | Phosphatidylethanol [Mass/volume] in Blood | 46 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 65.7 kg, BMI 22.7; waist 87 cm; blood pressure 122/78, pulse 74 |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements |
| Psychiatric | Euthymic; organized; no psychotic features; speech normal in rate |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisis | active | provisional | F29 | S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims. |
| Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking and its retrospective interpretation. |
| Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospital | active | confirmed | Z91.52 | S — Synthetic modern coding of the documented injury; no detail of the injury is recorded. |
| Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolved | resolved | confirmed | G25.71 | S — Synthetic medication side effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; in remission |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No psychotic symptoms; one day of racing ideas after a late night, managed with sleep |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 65.7 kg (BMI 22.7), up 2.7% from intake. Taken at 15 weeks rather than the CMID's 12, within the APA's four months |
| Examination | Waist circumference | Baseline, then yearly | Completed today | 87 cm |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 122/78 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Completed today | Fasting glucose 94 mg/dL; A1c 5.4%; yearly from now |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Completed today | Total cholesterol 191, LDL 112, HDL 50, triglycerides 142 mg/dL; yearly from now |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Deferred | PHQ-9 6 today, item 9 scored 0. No PHQ-9 was taken in the seven weeks since the six-week visit, longer than the monthly measure advised during acute treatment, because no visit fell in that time. No harm resulted: the score fell from 8 to 6 and the care coordinator saw him weekly. Corrective action: the care coordinator now gives the PHQ-9 monthly between visits |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; no firearm access |
| Self-management | Sleep | Every visit | Completed today | About seven hours; in bed by midnight |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 46 ng/mL |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 33, ALT 31, GGT 49 U/L, normal |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly; supported work plan: selling his paintings again |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Preventive visit in eight weeks. Six-month review with the AIMS, PEth, liver tests, and blood count. Care coordinator monthly, with the PHQ-9. Next scheduled visit 2026-06-15: periodic adult preventive visit. [S]